Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

Snap’s flagship product is the smartphone app Snapchat, which allows its users to communicate via ephemeral short videos and ...

Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...

Amgen AMGN reported third ... Total revenues of $8.51 billion came in line with the Zacks Consensus Estimate. Total revenues rose 23% year over year. Total product revenues increased 24% from ...

Amgen’s third-quarter product sales grew 24% (or 8% excluding ... Management raised its top-line guidance for 2024 by $100 million at the midpoint to $33 billion-$33.8 billion and narrowed ...

Total product revenues increased ... interested in the progress of Amgen’s GLP-1 receptor candidate, MariTide (maridebart cafraglutide), for obesity. Top-line 52-week data from the phase II ...

While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on ...

My name is Julianne, and I will be your conference facilitator today for Amgen's third quarter 2024 financial results ...

In the second quarter, Amgen's product net sales climbed by 20% year ... one of the fastest-growing categories of medicine. A top-line data readout is expected this year with the company already ...